741 related articles for article (PubMed ID: 37506675)
1. Long-term Cardiovascular Adverse Events Induced by Fluoroquinolones: A Retrospective Case-control Study.
Algaidi SH; Alghamdi DI; Algheffari SG; Alzahrani RA; Thabit AK; Hafiz AM
J Cardiovasc Pharmacol; 2023 Nov; 82(5):400-406. PubMed ID: 37506675
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency.
Bennett AC; Bennett CL; Witherspoon BJ; Knopf KB
Expert Opin Drug Saf; 2019 Nov; 18(11):1055-1063. PubMed ID: 31500468
[No Abstract] [Full Text] [Related]
3. Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan.
Chou HW; Wang JL; Chang CH; Lee JJ; Shau WY; Lai MS
Clin Infect Dis; 2013 Oct; 57(7):971-80. PubMed ID: 23948133
[TBL] [Abstract][Full Text] [Related]
4. Fluoroquinolone-Related Neuropsychiatric Events in Hospitalized Veterans.
Sellick J; Mergenhagen K; Morris L; Feuz L; Horey A; Risbood V; Wojciechowski A; Ruh C; Bednarczyk E; Conway E; Ott M
Psychosomatics; 2018; 59(3):259-266. PubMed ID: 29275962
[TBL] [Abstract][Full Text] [Related]
5. Oral Fluoroquinolones and Risk of Mitral and Aortic Regurgitation.
Etminan M; Sodhi M; Ganjizadeh-Zavareh S; Carleton B; Kezouh A; Brophy JM
J Am Coll Cardiol; 2019 Sep; 74(11):1444-1450. PubMed ID: 31514945
[TBL] [Abstract][Full Text] [Related]
6. Oral fluoroquinolones and risk of aortic or mitral regurgitation: a nationwide nested case-control study.
Strange JE; Holt A; Blanche P; Gislason G; Torp-Pedersen C; Christensen DM; Hansen ML; Lamberts M; Schou M; Olesen JB; Fosbøl EL; Køber L; Rasmussen PV
Eur Heart J; 2021 Aug; 42(30):2899-2908. PubMed ID: 34245252
[TBL] [Abstract][Full Text] [Related]
7. Effects of three fluoroquinolones on QT analysis after standard treatment courses.
Tsikouris JP; Peeters MJ; Cox CD; Meyerrose GE; Seifert CF
Ann Noninvasive Electrocardiol; 2006 Jan; 11(1):52-6. PubMed ID: 16472283
[TBL] [Abstract][Full Text] [Related]
8. Assessing fluoroquinolone-associated aortic aneurysm and dissection: Data mining of the public version of the FDA adverse event reporting system.
Meng L; Huang J; Jia Y; Huang H; Qiu F; Sun S
Int J Clin Pract; 2019 May; 73(5):e13331. PubMed ID: 30809871
[TBL] [Abstract][Full Text] [Related]
9. Risk of hepatotoxicity associated with fluoroquinolones: a national case-control safety study.
Alshammari TM; Larrat EP; Morrill HJ; Caffrey AR; Quilliam BJ; LaPlante KL
Am J Health Syst Pharm; 2014 Jan; 71(1):37-43. PubMed ID: 24352180
[TBL] [Abstract][Full Text] [Related]
10. Effects of three fluoroquinolones on QT interval in healthy adults after single doses.
Noel GJ; Natarajan J; Chien S; Hunt TL; Goodman DB; Abels R
Clin Pharmacol Ther; 2003 Apr; 73(4):292-303. PubMed ID: 12709719
[TBL] [Abstract][Full Text] [Related]
11. Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: a Taiwanese nationwide study.
Chou HW; Wang JL; Chang CH; Lai CL; Lai MS; Chan KA
Clin Infect Dis; 2015 Feb; 60(4):566-77. PubMed ID: 25409476
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility of hamsters to infection by historic and epidemic BI Clostridium difficile strains during daily administration of three fluoroquinolones.
Phillips ST; Nagaro K; Sambol SP; Johnson S; Gerding DN
Anaerobe; 2011 Aug; 17(4):166-9. PubMed ID: 21511046
[TBL] [Abstract][Full Text] [Related]
13. A VigiBase descriptive study of fluoroquinolone induced disabling and potentially permanent musculoskeletal and connective tissue disorders.
Huruba M; Farcas A; Leucuta DC; Bucsa C; Sipos M; Mogosan C
Sci Rep; 2021 Jul; 11(1):14375. PubMed ID: 34257376
[TBL] [Abstract][Full Text] [Related]
14. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.
Frothingham R
Pharmacotherapy; 2001 Dec; 21(12):1468-72. PubMed ID: 11765299
[TBL] [Abstract][Full Text] [Related]
15. Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant "clinical" event?
Makaryus AN; Byrns K; Makaryus MN; Natarajan U; Singer C; Goldner B
South Med J; 2006 Jan; 99(1):52-6. PubMed ID: 16466123
[TBL] [Abstract][Full Text] [Related]
16. US-based emergency department visits for fluoroquinolone-associated hypersensitivity reactions.
Jones SC; Budnitz DS; Sorbello A; Mehta H
Pharmacoepidemiol Drug Saf; 2013 Oct; 22(10):1099-106. PubMed ID: 23963962
[TBL] [Abstract][Full Text] [Related]
17. Effects of the Fluoroquinolones Moxifloxacin and Levofloxacin on the QT Subintervals: Sex Differences in Ventricular Repolarization.
Täubel J; Prasad K; Rosano G; Ferber G; Wibberley H; Cole ST; Van Langenhoven L; Fernandes S; Djumanov D; Sugiyama A
J Clin Pharmacol; 2020 Mar; 60(3):400-408. PubMed ID: 31637733
[TBL] [Abstract][Full Text] [Related]
18. Weighing the adverse cardiac effects of fluoroquinolones: A risk perspective.
Mehrzad R; Barza M
J Clin Pharmacol; 2015 Nov; 55(11):1198-206. PubMed ID: 26011799
[TBL] [Abstract][Full Text] [Related]
19. Association of oral ciprofloxacin, levofloxacin, ofloxacin and moxifloxacin with the risk of serious ventricular arrhythmia: a nationwide cohort study in Korea.
Cho Y; Park HS
BMJ Open; 2018 Sep; 8(9):e020974. PubMed ID: 30269062
[TBL] [Abstract][Full Text] [Related]
20. Moxifloxacin versus levofloxacin or ciprofloxacin prophylaxis in acute myeloid leukemia patients receiving chemotherapy.
Przybylski DJ; Reeves DJ
Support Care Cancer; 2017 Dec; 25(12):3715-3721. PubMed ID: 28660351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
